EGFR inhibitors (SpringWorks Therapeutics/Stanford Medicine)

N/A

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameEGFR inhibitors (SpringWorks Therapeutics/Stanford Medicine)
Drug Alias NameEGFR family tyrosine kinase receptor inhibitor (SpringWorks Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesStanford University School of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesSpringworks Therapeutics Inc
Inactive CompaniesStanford University School of Medicine
Active IndicationsLung Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A